CD274 and cancer: Canceling palmitoylation by knocking out ZDHHC3/9 or introducing the C272A mutation in PD-L1 can reduce the expression and cell surface distribution of PD-L1 and make cancer cells sensitive to T cell-mediated killing in vitro [117, 138].